Unknown

Dataset Information

Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA.


ABSTRACT:

Study objective

Obstructive sleep apnea is a common and serious sleep disorder for which treatment remains challenging due to lack of adherence to approved therapies. Previous pharmacological studies addressing sleep-related upper airway muscle hypotonia suggested that the combination of atomoxetine and oxybutynin is effective in treating obstructive sleep apnea. The current study is with aroxybutynin (AD109), a new enantiomerically pure form of oxybutynin with better safety profile compared to racemic oxybutynin.

Methods

This was a randomized, double-blind, placebo-controlled, crossover study in patients with mild to moderate obstructive sleep apnea. Each received low-dose AD109 (37.5/2.5 mg), high-dose AD109 (75/2.5 mg), and placebo at bedtime across 3 overnight periods in

SUBMITTER: Rosenberg R 

PROVIDER: S-EPMC9713910 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature